Collaborations leverage Strategic partnerships with AbbVie for ABBV-RGX-314 and ongoing collaboration opportunities around AAV Therapeutics suggest expansion potential in ophthalmology and rare diseases through co-development or co-commercialization with large pharma.

Late-stage momentum Positive topline data from AFFINITY Duchenne trial for RGX-202 and a clear upcoming catalyst calendar create conversations for potential licensing, partnerships, or milestone-driven collaborations with investors and pharma buyers seeking near-term value.

Clinical pipeline breadth AAV Therapeutics platform spanning retinal diseases, Duchenne muscular dystrophy, and rare disorders presents multiple entry points for partner engagement, including co-development of gene therapies and access to diversified rare disease portfolios.

Financial readiness Moderate revenue with substantial funding runway positions REGENXBIO to pursue partnerships, milestone-based deals, and research collaborations without immediate dilution pressure, appealing to partners seeking financial safety nets.

Market visibility Active investor engagement and regular conference participation, plus documented patient-treated scale of AAV therapies, enhances credibility for business development outreach focused on strategic alliances, co-funded trials, and global commercialization rights.